Drug intelligence / Profile preview

ILB-2201

Development stage: Preclinical
Lead developer: Innolake Biopharm
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

ILB-2201 is a preclinical-stage bispecific antibody (BsAb) developed by Innolake Biopharm for the treatment of various oncology indications. It is designed to simultaneously target Programmed Death-Ligand 1 (PD-L1) and Vascular Endothelial Growth Factor (VEGF). By dual-targeting these pathways, ILB-2201 aims to combine the immune-checkpoint inhibition of the PD-1/PD-L1 axis with the anti-angiogenic effects of VEGF inhibition, potentially overcoming resistance to monotherapies and enhancing anti-tumor efficacy.

Targets

CD274 (Programmed cell death protein 1 ligand 1)PGF (Placental Growth Factor)VEGFA (Vascular endothelial growth factor A)VEGFB (Vascular endothelial growth factor B)

Beyond the preview

Go deeper on ILB-2201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ILB-2201.

Explore the full profile